Cytokinetics prepares for Aficamten's regulatory decision

Cytokinetics is preparing for a key regulatory decision on its drug Aficamten, aimed at treating obstructive hypertrophic cardiomyopathy (oHCM), with a PDUFA date set for September 26. The company is also conducting four additional phase 3 trials for pediatric oHCM and nonobstructive hypertrophic cardiomyopathy (nHCM). The upcoming decision marks a significant step for Cytokinetics, as commercial success remains uncertain despite the progress in clinical trials.